(March 15 21:17) Forbes.com
On Monday, March 13th, the VA announced it is covering the Alzheimer’s drug lecanemab (Leqembi), with conditions of reimbursement - inclusion and exclusion criteria - that are consistent with but also go well beyond the FDA label.
You can find the original article
here